Inactive Instrument

Agentix Corp. Stock price Other OTC

Equities

AGTX

US00848A1034

Pharmaceuticals

Sales 2022 - Sales 2023 - Capitalization 3.91M
Net income 2022 -3M Net income 2023 -1M EV / Sales 2022 -
Net cash position 2022 145 Net Debt 2023 37.63K EV / Sales 2023 -
P/E ratio 2022
-2.35 x
P/E ratio 2023
-2.86 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 76.47%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chairman 44 20-12-13
Chief Tech/Sci/R&D Officer - -
Comptroller/Controller/Auditor - -
Members of the board TitleAgeSince
Director/Board Member 54 20-07-01
Chairman 44 20-12-13
More insiders
Agentix Corp. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic agents for the treatment of metabolic diseases like Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its pipeline includes AGTX-2004 and AGTX-2003. AGTX-2004 is a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM). AGTX-2003 is a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease. The Company is focused on the development of synthetic agonists, inverse agonists, and antagonists, which modulate the endocannabinoid system (ECS). The ECS is the regulatory system which governs metabolism. The Company’s wholly owned subsidiaries include GSL Healthcare, Inc., Agentix Australia Pty Ltd, and Applied Biopharma LLC.
More about the company
  1. Stock
  2. Equities
  3. Stock Agentix Corp.
  4. Stock Agentix Corp. - Other OTC